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Advances in neonatal intensive care
have decreased the incidence and mor-
bidity of chronic lung disease. How-
ever, chronic lung disease remains an
important issue for clinical and public
health because this illness is associated
with chronic respiratory difficulties,
prolonged and recurrent hospitaliza-
tion, and increased incidence of neuro-
logical disabilities, growth restriction,
and death.
Chronic lung disease following
lung injury is one of the most frustrat-
ing illnesses in modern neonatal medi-
cine. Despite surfactant replacement
therapy and other improvements in
neonatal care, there has not been a dra-
matic decrease in its incidence.
The issues surrounding therapy of
neonatal chronic lung disease are com-
plex. Many different therapeutic mo-
dalities have been investigated, and a
systematic review of controlled trials in
the scientific literature is needed in or-
der to determine which therapies have
adequate proof of efficacy.
There are numerous studies on the
use of parenteral or/and inhaled corti-
costeroids in the treatment of chronic
lung disease. Longer and shorter cor-
ticosteroid regimens have been evalu-
ated. Dexamethasone usage has be-
come widespread due to its immediate
short-term efficacy, but data concern-
ing long-term pulmonary effects
should be obtained.
Non-pulmonary effects of dexam-
ethasone therapy may be significant
and can be divided into two categories.
The first are usually transient adverse
effects that are not difficult to manage
clinically. These include hyperglyce-
mia, hypertension, elevation of the
neutrophil count, and protein catabo-
lism with associated poor weight gain.
The second group of adverse effects
includes those which are less common,
but warrant concern because of their
potential to adversely effect the ultimate
outcome of the infant, such as intesti-
nal perforation and gastrointestinal hem-
orrhage, increased risk of severe retin-
opathy of prematurity, an elevated risk
of infection, and the suppression of the
hypothalamic-pituitary-adrenal axis.
Observations of children treated with
systemic glucocorticoids that suggest
that the risk of growth suppression is
decreased when the frequency of ad-
ministration is reduced also point to ef-
fects on the hypothalamic-pituitary-ad-
renal axis. Furthermore, supporting evi-
dence comes from studies in adults,
which have assessed secretory profiles
of cortisol during treatment with exog-
enous glucocorticoids.
The risk of suppression of the hypo-
thalamic-pituitary-adrenal axis depends
on the timing and frequency of dosing,
suggesting that systemic adverse effects
of exogenous corticoids may reflect an
interaction with hormonal circadian
rhythms. Regarding growth-suppressive
effects, the underlying pathophysiologic
mechanisms are probably multifactorial,
with the involvement of a combination
of altered central endocrine and periph-
eral end-organ responsiveness to many
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physiologic regulators of the growth
process.
The timing, dose, route of adminis-
tration, and duration of therapy required
to achieve maximal response with mini-
mal adverse effects in infants with
chronic lung disease remain uncertain.
The two most important ways to
prevent chronic lung disease, which
have been known for decades, are to
delay the premature labor and to use
prenatal corticosteroid therapy. Re-
search on other methods of accelerat-
ing pulmonary maturity are underway.
Until then, neonatologists continue to
deal with increasing numbers of infants
for whom neonatal chronic lung dis-
ease is the price of survival.
